Profoundly Disturbed Lipoproteins in Cirrhotic Patients: Role of Lipoprotein-Z, a Hepatotoxic LDL-like Lipoprotein.
HDL-cholesterol
LP-Z
NMR
cirrhosis
lipid profile
orthotopic liver transplantation
Journal
Journal of clinical medicine
ISSN: 2077-0383
Titre abrégé: J Clin Med
Pays: Switzerland
ID NLM: 101606588
Informations de publication
Date de publication:
24 Feb 2022
24 Feb 2022
Historique:
received:
07
01
2022
revised:
20
02
2022
accepted:
23
02
2022
entrez:
10
3
2022
pubmed:
11
3
2022
medline:
11
3
2022
Statut:
epublish
Résumé
Detailed information regarding lipoprotein concentrations and subfractions in cirrhotic patients before and after orthotopic liver transplantation (OLT) is lacking. Lipoprotein-Z (LP-Z) is a recently characterised abnormal, hepatotoxic free cholesterol-rich low-density lipoprotein (LDL)-like lipoprotein. We determined the lipoprotein profiles, including LP-Z, in cirrhotic patients and OLT recipients and assessed the prognostic significance of LP-Z on the OLT waiting list. We performed analyses in cirrhotic transplant candidates and non-cirrhotic OLT recipients. A population-based cohort was used as reference. The setting was a University hospital. Lipoprotein particle concentrations and subfractions were measured by nuclear magnetic resonance spectroscopy. In the cirrhotic patients (N = 130), most measures of triglyceride-rich lipoproteins (TRL), LDL, and high-density lipoproteins (HDL) were much lower compared to the OLT recipients (N = 372) and controls (N = 6027) (p < 0.01). In the OLT recipients, many lipoprotein variables were modestly lower, but HDL-cholesterol, triglycerides, and TRL and HDL size were greater vs. the control population. LP-Z was measurable in 40 cirrhotic patients and 3 OLT recipients (30.8% vs. 0.8%, p < 0.001). The cirrhotic patients with measurable LP-Z levels had profoundly lower HDL-cholesterol and particle concentrations (p < 0.001), and worse Child Pugh Turcotte classifications and MELD scores. The presence of LP-Z (adjusted for age, sex, and MELD score) predicted worse survival in cirrhotic patients (HR per 1 LnSD increment: 1.11, 95%CI 1.03−1.19, p = 0.003). In conclusion, cirrhotic patients have considerably lower plasma concentrations of all major lipoprotein classes with changes in lipoprotein subfraction distribution. After OLT, these lipoprotein abnormalities are in part reversed. LP-Z is associated with cirrhosis. Its presence may translate in disturbed HDL metabolism and worse survival.
Identifiants
pubmed: 35268313
pii: jcm11051223
doi: 10.3390/jcm11051223
pmc: PMC8910943
pii:
doi:
Types de publication
Journal Article
Langues
eng
Références
J Lipid Res. 2019 May;60(5):1050-1057
pubmed: 30808683
N Engl J Med. 1970 Oct 15;283(16):841-6
pubmed: 5458034
Transplantation. 2002 Mar 27;73(6):901-6
pubmed: 11923689
Circulation. 2010 Aug 3;122(5):470-7
pubmed: 20644014
Liver Transpl. 2011 Jan;17(1):15-22
pubmed: 21254340
Clin Sci Mol Med. 1978 Apr;54(4):369-79
pubmed: 205385
Circulation. 2020 Aug 18;142(7):657-669
pubmed: 32804568
Biomolecules. 2020 Mar 21;10(3):
pubmed: 32245262
Hepatology. 2001 Feb;33(2):464-70
pubmed: 11172350
J Clin Chem Clin Biochem. 1987 Sep;25(9):541-51
pubmed: 3316478
Clin Sci (Lond). 1979 Jan;56(6):575-83
pubmed: 225095
BMJ Open. 2018 Dec 31;8(12):e024502
pubmed: 30598488
Nutrients. 2019 Mar 26;11(3):
pubmed: 30917546
Biochem J. 1976 Aug 1;157(2):401-7
pubmed: 183749
Lipids Health Dis. 2020 Dec 1;19(1):247
pubmed: 33261644
Am J Pathol. 2011 Apr;178(4):1429-33
pubmed: 21406176
J Clin Med. 2020 Sep 10;9(9):
pubmed: 32927635
Transplant Rev (Orlando). 2015 Apr;29(2):93-102
pubmed: 25227328
Curr Opin Lipidol. 2020 Aug;31(4):232-237
pubmed: 32618730
Nat Med. 2001 Jul;7(7):847-52
pubmed: 11433351
Lancet Gastroenterol Hepatol. 2020 Mar;5(3):245-266
pubmed: 31981519
Liver Transpl. 2013 Jan;19(1):3-26
pubmed: 23281277
Hepatology. 2022 Apr;75(4):968-982
pubmed: 34662439
Transpl Int. 1998;11(2):137-42
pubmed: 9561680
Hepatology. 2012 Aug;56(2):415-8
pubmed: 22430840
Eur J Clin Invest. 2003 Dec;33(12):1051-69
pubmed: 14636288
Clin Biochem. 2015 Feb;48(3):148-55
pubmed: 25438074
Transplantation. 1995 Nov 15;60(9):1057-60
pubmed: 7491685
Clin Biochem. 2018 Apr;54:92-99
pubmed: 29432757
Br J Surg. 1973 Aug;60(8):646-9
pubmed: 4541913
J Am Coll Cardiol. 2013 Jan 29;61(4):427-436
pubmed: 23265341
Eur J Gastroenterol Hepatol. 2007 Jun;19(6):521-2
pubmed: 17489065
Hepat Mon. 2010 Fall;10(4):285-8
pubmed: 22312394
J Biol Chem. 1987 Dec 5;262(34):16271-4
pubmed: 3316217
J Clin Endocrinol Metab. 2013 Aug;98(8):E1352-9
pubmed: 23690306
JACC Heart Fail. 2019 Feb;7(2):87-97
pubmed: 30553904
J Gastroenterol Hepatol. 1993 Nov-Dec;8(6):569-73
pubmed: 8280846
Dig Dis Sci. 2018 Jan;63(1):16-26
pubmed: 29177578
Arq Gastroenterol. 2015 Jul-Sep;52(3):210-5
pubmed: 26486289
J Clin Med. 2019 Dec 24;9(1):
pubmed: 31878321
Liver Transpl Surg. 1999 May;5(3):204-8
pubmed: 10226111
Scand J Clin Lab Invest Suppl. 1974;137:115-20
pubmed: 4367610
J Clin Endocrinol Metab. 2005 Jul;90(7):4198-204
pubmed: 15840744
Clin Exp Med. 2014 Nov;14(4):417-21
pubmed: 24122348
PLoS One. 2016 Jan 25;11(1):e0145719
pubmed: 26808474
Clin Transplant. 1996 Apr;10(2):213-7
pubmed: 8664522
J Clin Endocrinol Metab. 2021 May 13;106(6):1761-1772
pubmed: 33567068
Clin Biochem. 2014 Nov;47(16-17):203-10
pubmed: 25079243
Clin Lab Med. 2006 Dec;26(4):847-70
pubmed: 17110242
Gut. 1978 Jun;19(6):526-30
pubmed: 355066
Metabolism. 1993 Jan;42(1):19-23
pubmed: 8446043
J Am Coll Cardiol. 2020 May 5;75(17):2122-2135
pubmed: 32354380
Biochim Biophys Acta. 2000 Dec 15;1529(1-3):245-56
pubmed: 11111093
Transplantation. 1995 Dec 27;60(12):1443-50
pubmed: 8545872
J Intern Med. 2011 Feb;269(2):232-42
pubmed: 21129046
Cardiovasc Diabetol. 2021 Jul 28;20(1):156
pubmed: 34321006
Eur J Clin Invest. 1974 Dec 5;4(6):419-28
pubmed: 4374360
Gastroenterology. 2003 Jan;124(1):91-6
pubmed: 12512033
Surgery. 1995 Oct;118(4):783-6; discussion 786-8
pubmed: 7570337